SUPN - Company ID 0001356576
The table below shows SUPERNUS PHARMACEUTICALS, INC.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $128.45M | $69.33M | $93.12M | $203.43M | $288.64M | $181.38M |
| Short-term investments | - | - | $368.21M | $136.25M | $133.89M | $165.69M |
| Receivables | $187.80M | $142.08M | $165.50M | $148.93M | $140.88M | $87.33M |
| Inventory | $112.48M | $54.29M | $91.54M | $85.96M | $48.33M | $26.63M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $644.18M |
| $686.07M |
| $734.15M |
| $601.59M |
| $630.42M |
| $472.64M |
| Property, plant & equipment | $10.53M | $11.54M | $15.17M | - | $37.82M | $17.07M |
| Goodwill | $124.88M | $117.02M | $117.02M | $117.52M | $77.91M | - |
| Total assets | $1.45B | $1.37B | $1.70B | $1.69B | $1.50B | $1.16B |
| Accounts payable | $2.68M | $4.59M | $10.54M | $9.33M | $6.15M | $10.14M |
| Total current liabilities | $338.17M | $292.40M | $687.96M | $315.38M | $245.11M | $160.59M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $390.93M | $332.34M | $816.30M | $873.30M | $759.24M | $564.85M |
| Retained earnings | $517.88M | $556.43M | $481.25M | $379.92M | $326.50M | $199.55M |
| Total equity | $1.06B | $1.04B | $886.20M | $815.85M | $744.86M | $595.43M |